DexCom Inc. (DXCM) shares experienced a significant after-hours plunge of 5.89% following the release of its fourth-quarter financial results.

The medical device company reported quarterly adjusted earnings of $0.68 per share, beating the analyst consensus estimate of $0.65. Revenue for the quarter reached $1.26 billion, also surpassing expectations of $1.25 billion and marking an increase from the same period last year.

Despite the earnings and revenue beat, the stock sold off in post-market trading. A key factor appears to be the company's forward guidance. DexCom reiterated its full-year 2026 revenue outlook of $5.16 billion to $5.25 billion, which brackets the consensus estimate of $5.23 billion. The lack of a guidance raise following the quarterly beat may have disappointed investors who were anticipating more robust future projections.